|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cerebrospinal fluid (CSF) levels of two soluble biomarkers, glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL), have been shown to associate with multiple sclerosis (MS) disease progression.
|
30570436 |
2020 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients.
|
31611264 |
2019 |
|
Multiple Sclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We conducted a systematic review and meta-analysis of case-control studies that have measured neurofilament light chain (NfL) levels in cerebrospinal fluid (CSF) of people with MS (pwMS), in order to determine whether, and to what degree, CSF NfL levels differentiate MS from controls, or the subtypes or stages of MS from each other.
|
31123141 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we review the current knowledge about CSF NfL determination in MS, clinically isolated syndrome, and radiologically isolated syndrome, and critically discuss how CSF NfL measurement may contribute to therapeutic decision-making in these patients.
|
31314847 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis.
|
30912689 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Vitamin D supplementation and neurofilament light chain in multiple sclerosis.
|
30317548 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess the prognostic role of serum neurofilament light chains (NfL) for clinically defined multiple sclerosis (CDMS) and McDonald 2017 multiple sclerosis (MS) in patients with clinically isolated syndromes (CIS).
|
30635483 |
2019 |
|
Multiple Sclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.
|
31610732 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cerebrospinal fluid (CSF) neurofilament light chain (NfL) is a promising marker of axonal damage in MS.
|
31129709 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To describe the evolution of intrathecal immunoglobulin and neurofilament light (NFL) over time in MS patients treated with aHSCT.
|
31347948 |
2019 |
|
Multiple Sclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study provides preliminary evidence for an association between CSF NfL levels and cognition in progressive forms of MS, which requires validation in larger samples.
|
30982375 |
2019 |
|
Multiple Sclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Neurofilament light chain (NfL) is a promising marker of disease activity/treatment response in multiple sclerosis (MS), although its predictive value for long-term clinical outcomes remains unclear.
|
31680621 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> Neurofilament light chain protein (NFL) and chitinase3-like1 (CHI3L1) have gained importance recently as prognostic biomarkers in multiple sclerosis (MS).
|
31608004 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study analyzed serum neurofilament light chains (NfL) in 2 European cohorts of 312 multiple sclerosis (MS) patients to investigate whether NfL are biomarkers of progressive multifocal leukoencephalopathy (PML) during natalizumab treatment.
|
30761586 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.
|
30113249 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.
|
30737333 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neurofilament light chain (NF-L) appears the most promising biomarker in MS patients, and there is now little doubt that NF-L should have a role in the follow-up of MS patients.
|
31024432 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A promising biomarker for axonal damage early in the disease course of multiple sclerosis (MS) is neurofilament light chain (NfL).
|
29774770 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cerebrospinal fluid (CSF) neurofilament light chain (NfL) has shown to have prognostic value in MS patients.
|
31404762 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum NfL measured during the first few years after the clinical onset of MS contributed to the prediction of 10-year MRI brain lesion load and atrophy.
|
30564615 |
2018 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neurofilament light chain (NFL) is a cerebrospinal fluid (CSF) marker of neuroaxonal damage in multiple sclerosis (MS).
|
28627962 |
2018 |
|
Multiple Sclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain.
|
29797629 |
2018 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Articles in English that evaluated the utility of NFL in CSF and blood in the diagnosis of MS were included.
|
30214214 |
2018 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cerebrospinal fluid (CSF) osteopontin (OPN) and neurofilament light chain (NF-L) have been proposed as candidate surrogate markers of inflammatory and neurodegenerative processes in MS.
|
28537100 |
2018 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
While neurofilament light chain (NfL) measurement in serum is a well-established marker of neuroaxonal damage in multiple sclerosis (MS), data on astroglial markers in serum are missing.
|
30287870 |
2018 |